EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Bernhard Hellmich(Comenius University Bratislava), David Jayne(University of Cambridge)
Cited by 635
Related Papers
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
|Annals of the Rheumatic Diseases|2019|1.1k
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
|Annals of the Rheumatic Diseases|2019|226